Atea Pharmaceuticals Inc
For the period ended Jun 20, 2025. Filed Apr 29, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 20, 2025 · Filed Apr 29, 2025
Use the contents to explore the available documents and sections.
Contents
Proxy Statement Summary
Advancing Oral Antiviral Therapies
We are a clinical-stage biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry biology, biochemistry and virology to discover and develop novel orally administered product candidates to treat serious viral diseases. Our lead product candidate is a regimen consisting of bemnifosbuvir and ruzasvir which we are developing for the treatment of chronic Hepatitis C virus (“HCV”) infection. In April 2025, we commenced enrollment of patients in C-Beyond, a Phase 3 clinical trial constituting one of two Phase 3 clinical trials in our HCV registrational program.
The HCV commercial market is substantial and undertreatment of infections combined with high rates of annual incidence of infection presents an attractive opportunity for an improved HCV antiviral product.
Our Board Provides Robust Oversight of Management
Our Board includes high-quality and accomplished directors who contribute complementary skills, experience, backgrounds and perspectives that facilitate robust oversight of management and the Company.
With more than half of our independent directors appointed since 2020, the Board has been significantly refreshed welcoming new perspectives while retaining the institutional knowledge possessed by our directors with longer tenure.
Our Board is focused on ensuring the execution of our strategy, enhancing performance and creating an environment that increases operational efficiency – all of which will contribute to Atea’s long-term growth and the creation of sustainable stockholder value.
| Board Highlights (Including the appointment of Howard H. Berman, PhD, following the Annual Meeting) | ||
|---|---|---|
| Directors with PhD or MD | Board Independence | New Directors Since 2020 |
Director Skillsets
Our Corporate Governance Promotes Accountability
The governance structure adopted at the time of Atea’s initial public offering (“IPO”) less than five years ago reflects the Board’s intentions to allow leadership to drive the creation of long-term stockholder value by focusing, in a financially disciplined manner, on the discovery and development of first- orbest-in-class oral antiviral therapeutics.
| Governance Principles | Corporate Governance Practice | |
|---|---|---|
| Accountability to Stockholders | One vote per share of Common Stock | |
| No dual class or unequal-voting structure | ||
| No poison pill | ||
| Simple majority vote on merger proposals | ||
| Robust Independence | 7 of our 8 directors are independent (as is Howard H. Berman, PhD, who has been appointed to serve on our Board effective immediately following the Annual Meeting) | |
| 5 new independent directors appointed since 2020 (inclusive of Dr. Berman) | ||
| Independent Lead Director with delineated role and approval authority | ||
| Our independent directors regularly meet in executive sessions. | ||
| All four standing Board committees—Audit, Compensation, Nominating and Corporate Governance, and Strategy and Public Policy—are independent | ||
| Comprehensive Evaluation and Risk Oversight | Our Board periodically reviews its performance, as well as the performance of each of its standing committees | |
| Our Compensation Committee evaluates our CEO’s performance annually and oversees management of risks associated with our compensation policies and programs | ||
| Our Nominating and Corporate Governance Committee oversees management of risks associated with overall governance and Board composition matters | ||
| Our Audit Committee oversees management of financial and cybersecurity risks | ||
| Strong Alignment of Interests with Stockholders | We have a clawback policy that applies to both cash and equity incentives and is triggered by a financial restatement | |
| Our directors and executive officers are prohibited from pledging or hedging transactions |
Executive Compensation is Aligned with Company Performance
Despite being a smaller reporting company under SEC rules, we voluntarily provide supplementary disclosure that provides transparency of our compensation structure
Our Compensation Committee designs incentives based on Company performance that both emphasize the creation of sustainable long-term stockholder value and attract, motivate and retain highly qualified and experienced executives.
| Our Executive Compensation Philosophy is designed to reward executives for actions that create incremental stockholder value and align the interests of stockholders and executives | |
|---|---|
| Pay for Performance | Reward executives for actions that create incremental stockholder value |
| Align Interests | Ensure executives’ interests are aligned with long-term stockholders |
| Attract & Retain | Provide appropriate compensation for each executive relative to industry |
The design of our executive compensation program promotes performance alignment and protects stockholder interests.
| Design Feature | Rationale & Impact | Pay for Performance | Align Interests | Attract & Retain |
|---|---|---|---|---|
| Emphasize at-risk compensation | ➣ 84% of CEO 2024 target pay at risk | |||
| Balance short- and long-term incentives | ➣ Reward executives for actions that create stockholder value | |||
| Focus on equity pay mix | ➣ Approximately 50% of CEO 2024 equity granted as performance stock units (“PSUs”) | |||
| Link annual bonus to preset goals | ➣ Rewards executives for achieving strategic objectives ➣ No guaranteed bonuses | |||
For 2024, the resulting Target Pay mix was:
Our Commitment to Stockholder Engagement
Our Board appreciates stockholder feedback and regularly engages with stockholders to better understand their perspectives. The Board values stockholder feedback received as it serves as key input to Board and Committee discussions and ultimately informs decision-making. Since our 2020 IPO, we have regularly engaged with stockholders.
Following the 2024 Annual Meeting, we offered engagement calls to stockholders owning more than 50% of our outstanding shares of Common Stock. Of those, stockholders owning approximately 20% of our outstanding shares elected not to engage, reflecting they had no concerns that warranted a specific engagement conversation. Stockholders with whom we did meet sought generally to discuss our strategy and review our business, goals and performance. Meetings with stockholders included, in certain circumstances our independent directors exclusively, and in other circumstances, members of our senior management team.
Feedback received from our meetings with stockholders was shared directly with the full Board, and was a key input to Board and relevant Committee discussions.
Actions taken by the Compensation Committee in line with stockholder preferences include: ✓ Re-introduced PSUs as a significant part of the 2024 total compensation ✓ Provide enhanced voluntary disclosures to convey to stockholders the rationale, guiding principles and polices that our Compensation Committee and Board follow when determining compensation of our named executive officers (“NEOs”) ✓ Enhanced disclosure of our annual performance-based cash incentive to demonstrate the link between Company performance and preset, objective goals ✓ Committed to disclose Company performance against the preset long-term goals when the PSU performance period is completed
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.